

**Treating Fibromyalgia with Mindfulness-Based Stress Reduction –
Results from a Three-Armed Randomized Controlled Trial**

Stefan Schmidt ^{a,c,d,e,*}, Paul Grossman ^b, Barbara Schwarzer ^a, Susanne Jena ^a, Johannes
Naumann ^a, Harald Walach ^{c,d}

a Department of Environmental Health Sciences, University Medical Center, Freiburg, Germany

b Psychosomatic Medicine, University of Basel Hospital, Basel, Switzerland

c Institute for Transcultural Health Studies, European University Viadrina, Frankfurt (Oder), Germany

d Samueli Institute, European Office, Brain, Mind and Healing Programme, Germany

e Heymans Chair of Exceptional Human Experiences, University for the Humanistics, Utrecht, The Netherlands

* Corresponding author, request for reprints

Stefan Schmidt, PhD

Department of Environmental Health Sciences

University Medical Center Freiburg

Breisacherstr. 115b, 79106 Freiburg, Germany

Tel. +49-761-270-8305 Fax +49-761-270-8343

stefan.schmidt@uniklinik-freiburg.de

ClinicalTrials.gov Identifier: NCT00106275

Abstract

Mindfulness-based stress reduction (MBSR) is a structured eight-week group program teaching mindfulness meditation and mindful yoga exercises. MBSR aims to help participants develop non-judgmental awareness of moment-to-moment experience. Fibromyalgia is a clinical syndrome with chronic pain, fatigue and insomnia as major symptoms. Efficacy of MBSR for enhanced wellbeing of fibromyalgia patients was investigated in a three-armed trial, which was a follow-up to an earlier quasi-randomized investigation.

One-hundred-seventy-seven female patients were randomized to (1) MBSR, (2) an active control procedure controlling for nonspecific effects of MBSR, or (3) a wait list. The major outcome was health-related quality of life (HRQoL) four months post-treatment. Secondary outcomes were disorder-specific quality of life, depression, pain, anxiety, somatic complaints, and a proposed index of mindfulness.

Eighty-two percent of patients completed the study. There were no significant differences between groups on primary outcome, but patients, overall, improved in HRQoL at four-month follow-up ($p=.004$). Post hoc analyses showed that only MBSR manifested a significant pre-to-post-intervention improvement in HRQoL ($p=.02$). Furthermore, multivariate analysis of secondary measures indicated modest benefits for MBSR patients. MBSR yielded significant pre-to-post-intervention improvements in six of eight secondary outcome variables, the active control in three and the wait list in two.

In conclusion, primary outcome analyses did not support the efficacy of MBSR in fibromyalgia, although patients in the MBSR arm appeared to benefit most. Effect sizes were small compared to the earlier, quasi-randomized investigation. Several methodological aspects are discussed, e.g. patient burden, treatment preference and motivation, that may provide explanations for differences.

Keywords: Fibromyalgia – RCT – Mindfulness – MBSR – Behavioral Intervention – Chronic Pain

Introduction

Fibromyalgia is a frequently diagnosed pain disorder primarily affecting women, showing high comorbidity with other functional somatic disorders and depression [47]. So far no distinct cause or pathology has been identified. Recent research indicates that fibromyalgia patients may manifest dysfunctional pain processing of central origin [1], and possibly impaired cardiovascular autonomic regulation [36]. Pharmacological treatment of the disorder has proven difficult, perhaps, because of its nonspecific pathophysiology. Thus, central nervous agents, such as tricyclic antidepressants [25], selective serotonin and norepinephrine reuptake inhibitors [3,41] or pregabalin [16], have been found to be moderately successful but only for relatively short periods of time [15]. Only a few nonpharmacological interventions appear to confer even moderate benefits, i.e. mainly cardiovascular exercise, cognitive-behavioral therapy and patient education [18], or a combination of them [23]. However many of these benefits are also short-lived.

Another proposed behavioral intervention for fibromyalgia is mindfulness-based stress reduction (MBSR), an eight-week, structured group program employing mindfulness meditation techniques and mindful yoga exercises [27]. MBSR aims to help participants develop non-judgmental awareness of moment-to-moment experience, importantly within a context of openness, kindness, tolerance and acceptance of perceptible sensory, mental and emotional phenomena. A body of evidence indicates that MBSR can improve coping and health-related quality of life (HRQoL) in many chronic conditions, including chronic pain [20,37].

So far eight trials have assessed MBSR, specifically, or mindfulness-based techniques in combination with other educational/behavioral ones among patients with fibromyalgia. Studies in the latter category were either uncontrolled [14] or did not find significant differences in the primary outcome [4,33]. Of the five trials directly evaluating MBSR, one showed clinical improvement but was uncontrolled [29]; a later trial with a non-randomized

wait-list control group reported significant differences on several fibromyalgia related visual analogue scales (VAS), the Fibromyalgia Impact Questionnaire (FIQ $p=.05$) and the symptom checklist SCL90 ($p=.0001$) [19]. A third randomized investigation with wait-list controls showed significant improvements in depression [42], whereas a fourth uncontrolled trial study provided indications of significant changes in psychophysiological variables [32]. Finally, the fifth study is the direct forerunner of the current investigation [21]. In a quasi-randomized design, 39 female fibromyalgia patients received MBSR; 13 control patients were assigned to an active control procedure designed to match for non-specific effects of MBSR. MBSR showed strong effects in comparison to the control group for HRQoL (effect sizes ranged from $d=0.52$ to 1.12), pain ($d=1.10$), depression (0.39), anxiety (0.67) and coping abilities ($0.34-0.88$). In a three-year observational follow-up, the MBSR group patients maintained significant improvement in all these variables, compared to pre-intervention. On the basis of these positive findings, we decided to replicate and extend this study, adding an additional control group.

Health related quality of life (HRQoL) was chosen in this trial as primary outcome, because severely impaired HRQoL is a central feature of fibromyalgia for some people, and relatively strong effects upon HRQoL have been observed in earlier studies of MBSR and fibromyalgia, e.g. [21].

Methods

Design

A three-armed randomized trial was conducted, in which female patients were randomly assigned to either (i) MBSR (ii) an active control intervention aimed at equating the nonspecific features of MBSR or (iii) a wait-list control group. Primary endpoint was a measure of HRQoL (see also below) at short-term follow-up, 8 weeks post-intervention.

We hypothesized that (1) active treatments, i.e. MBSR and active control, would show greater improvement than wait-list control, and (2) MBSR patients would manifest greater benefits than the active control intervention. The primary outcome was overall score of HRQoL. Secondary outcomes were disease-specific (fibromyalgia) QoL, sleep quality, anxiety, depression general complaints, and pain sensation. All measures were assessed by means of standardized and validated self-report inventories.

Baseline measurements were completed after determination of eligibility (pre-intervention baseline, 0 weeks), and patients were subsequently allocated to one of the three study arms. Patients were again assessed after the 8-week intervention or waiting period (end of intervention). Patients were then asked to continue to practice their mindfulness exercises and homework for an additional 8 weeks, and they were evaluated a third time at short-term follow-up. Changes in outcome variables from pre-intervention to short-term follow-up were employed for the main outcome analysis.

Sample size was determined on the basis of our meta-analysis of controlled MBSR trials, in which we found a mean effect size of $d = 0.53$ [20]. This effect size results in $1-\beta = 0.89$ ($\alpha = .05$) for $N = 60$ patients per group or $N = 180$ patients overall. With maximal attrition assumed to be 20%, the power remains $1-\beta = 0.82$.

Participants

Women, 18-70 years of age, who currently suffered from fibromyalgia, as defined by the American College of Rheumatology (ACR) criteria [48], were eligible for the trial. Additional inclusion criteria were command of the German language, and motivation to participate. Exclusion criteria were life-threatening diseases, evidence of suppressed immune functioning or participation in other clinical trials. Participants were recruited via patient self-help groups, news media and referrals from general practitioners, rheumatologists and the University of Freiburg Medical Center Interdisciplinary Pain Unit. During an intake examination at the

hospital, patients were evaluated for all eligibility criteria and were examined by an experienced physician who employed ACR criteria to confirm diagnosis of fibromyalgia.

Informational brochures were then provided that briefly described the two interventions as alternative behavioral treatments potentially capable of enhancing the wellbeing of fibromyalgia patients. No suggestion was made about the superiority of either treatment. Information was collected concerning ongoing medical, pharmacological, psychotherapeutic or other interventions for the disorder, but patients were not asked to discontinue any treatments. This study was approved by the University of Freiburg Ethics commission, and all patients completed informed consent prior to enrollment.

Interventions

Consenting eligible patients were randomly assigned to one of three study arms: The experimental intervention (mindfulness-based stress reduction; MBSR), an active control intervention and a wait-list group. Patients in the intervention arms were told that two new innovative treatments were to be compared, one based on the concept of mindfulness (entailing meditation and yoga lessons, as well as homework), and the other based on health support techniques (entailing relaxation and stretching exercises, as well as homework). The active control group was referred to as the relaxation group. All patients participating in one of the two active treatment arms were also offered participation in their treatment of choice after completion of the trial.

MBSR

The MBSR intervention was closely based upon the original program [26] and was identical to that used in the earlier investigation [21]. It comprised an 8-week structured program with groups of up to 12 patients, taught by a single instructor. Participants took part in one 2.5-hour sessions every week, and an additional 7-h all-day session on a weekend day.

Each session covered specific exercises and topics within the context of mindfulness practice and training. These included various types of formal mindfulness practice, mindful awareness of dynamic yoga postures, and mindfulness during stressful situations and social interactions. The all-day retreat included a combination of previously employed and newly introduced mindfulness exercises. Upon enrollment, participants were asked to commit themselves to daily homework assignments of 45-60 min. Instructors were two women with university level degrees in educational counseling who had undergone MBSR training provided by the UMass Medical Center for Mindfulness, Worcester, Mass., USA. Each had at least 7 years of previous experience teaching MBSR, as well as experience teaching fibromyalgia patients.

Pre- and post-intervention one-hour personal interviews were conducted by each instructor to establish rapport and to help patients formulate realistic individual goals for the intervention. Post-intervention interviews addressed participants' personal experiences during the course and assessed the degree to which pre-treatment goals had been met.

Active Control Group

The active control intervention was planned to control for the nonspecific aspects of the MBSR curriculum and was very similar to that employed in the predecessor study [21]. It comprised of participation in an 8-week group of similar size and weekly format as the MBSR program taught by a single instructor. Additionally, equivalent amounts of social support and weekly topical educational discussions were provided. Employment of Jacobson Progressive Muscle Relaxation training (PMR), and fibromyalgia-specific gentle stretching exercises [7] served as counterparts for mindfulness elements of the MBSR curriculum. Homework assignments were similar in duration and intensity to those of the MBSR group. Patients received CDs with instructions for daily exercises. Pre- and post-intervention interviews were given by individual instructors using the same protocol as with the MBSR group. Instructors were two female psychologists with many years of group and relaxation training experience.

A manual similar to the one used in MBSR was written by SS¹. The trainers had an extensive preparation period and were regularly supervised by SS, who is a trained psychotherapy group supervisor. One notable difference between active interventions was the absence of an all-day session in the active control program.

None of the MBSR and Active Control group instructors had any other relationship with the study than providing course instruction.

Wait-list control

Patients randomized to this group received no active treatment but were offered their choice of either intervention at conclusion of the short-term follow-up period.

Primary Endpoint²

The *Quality of Life Profile for the Chronically Ill* (PLC) is a HRQoL inventory especially designed for patients suffering from chronic conditions [43]. It consists of 40 items and 6 subscales: Physical functioning, ability to relax and enjoy life, positive affect, negative affect, social contact and social integration. Scores of the six subscales can be summed to a total score. The inventory is well validated and was used in an earlier MBSR investigation with fibromyalgia patients [21].

Secondary Endpoints

The *Fibromyalgia Impact Questionnaire* (FIQ) consists of 20 items [9,38]. The first 11 items assess the physical functioning of the patients and can be combined to a single score. The next two items are related to overall wellbeing and to the capability to work. There are also seven visual analogue scales (VAS) that assess frequent fibromyalgia symptoms of pain, fatigue, stiffness and mood.

Depression was assessed by the *Center for Epidemiological Studies depression inventory* (CES-D) [24,40], a 20-item scale designed for the general population.

Anxiety was measured by the 20-item trait subscale of the *State-Trait-Anxiety-Inventory* (STAI) [31,45].

Quality of Sleep was assessed by the *Pittsburgh Sleep Quality Index* (PSQI) [5,10,11]. This inventory has 9 items; one item consists of ten sub-items, so that patients filled in 18 items overall.

Pain perception was assessed by means of the well validated *Pain Perception Scale* (PPS) [17]. This questionnaire consists of two subscales: sensory and affective pain, with 14 and 10 items, respectively.

Self-attribution of mindfulness was assessed with the 14-item short form of the *Freiburg Mindfulness Inventory* (FMI) [46].

Physical Symptoms was assessed using the well validated *Giessen Complaint Questionnaire* (GCQ) [8]. This inventory documents the presence and severity of 57 single symptoms and combines them into different scales. The scale 'general complaint level' consists of 24 items.

Co-occurring therapies were evaluated retrospectively every four weeks by asking patients about other ongoing therapies, medical appointments and medication changes.

Diaries were completed by patients during four one-week periods within the 8-week treatment phase (twice, weeks 3 and 7) and 8-week follow-up period (twice, weeks 3 and 7). During these weeks, patients were asked to keep a diary for a week of all medication taken, as well as the time, duration and type of daily practice related to the homework. Diaries were sent and returned by mail.

Interview data were also collected pre- and post-intervention. At the pre-intervention interview, patients were asked to formulate one to three personal goals they hoped to achieve. At the post-intervention interview, patients were asked to quantify the degree to which these goals had been achieved, employing an 11-point goal-attainment scale (GAS), which ranged

from -5 (not at all achieved) to +5 (achieved to far greater extent than expected) with the mid-point indicating the goal was reached to the level expected. During each interview, patients were also asked to indicate degree of *impairment experienced due to their condition* within the last two weeks on a visual analogue scale.

Ambulatory psychophysiological data: At baseline, end of intervention and short-term follow-up, patients were also assessed by means of an ambulatory psychophysiological monitor (LifeShirt, Vivometrics, CA, USA), during which they were asked to wear a vest-like garment for 24 hours during everyday life, with sensors for respiration, electrocardiogram and physical activity. The recorder also had a touch-sensitive display on which the patients completed a questionnaire at regular intervals during awake hours. Ambulatory results will be reported in a separate publication.

Clinical meaningful change: According to the current literature [12,22] there are two different approaches to determine a clinical meaningful change in a self-rating questionnaire. These are anchor-based and population-based techniques. While both methods are not completely satisfactory per se, we preferred the anchor-based approach, since this method includes an external reference point analogous to criterion validation. With this approach, a minimal clinically important difference (MCID) of the scale is determined by an external anchor, usually a single item asking for global change. An anchor-based estimate of MCID was available for only one of the eight scales we employed, i.e. the FIQ [6]. Another way to judge a meaningful clinical change is whether patients cross established thresholds [34]. For two other scales, the CES-D [24] and the PSQI (email by D. J. Buysse, 7/2/2010), cut-offs have been recommended. Scores above these cut-offs respectively indicate clinical risk of depression or sleeping problems. We considered traversing these cut-off values in either direction as a clinical meaningful change and report the data accordingly.

Randomization

Patients were randomized in blocks by a computer algorithm [35]. Block size was randomly chosen to be either three or six patients. Information regarding eligible patients entering the trial was sent to a study manager who otherwise had no contact with the patients. He then determined block size and randomized the patients, but only if there were enough patients to fill the next block. Patients were blind to the fact that MBSR was the experimental intervention, and the relaxation procedure, the control one. All personnel of the study centre handling the data or interacting with the patients during the whole course of the trial stayed blinded until the final analysis. Patients were encouraged to not tell the monitoring physician about their group assignment. Despite attempts to remain blinded, the study physician reported that patients occasionally volunteered information regarding allocation, and estimated this to occur in about 20% of the sample.

Statistical Analyses

Results are based upon intention-to-treat (ITT) analyses: Missing values of individual items of scales were replaced according to missing replacement procedures of the respective inventories. When not specified or when more items were missing than allowed for replacement using these procedures, overall scale values were replaced by a regression-based single imputation procedure (“predicted means”) by the software SOLAS 2.0 [44]. Predictors for the imputation process were the respective baseline values of age, group, educational background, housing situation and occupational level.

All analyses were performed by employing the General Linear Model (GLM). Comparisons of groups at baseline were calculated either by one-way analysis of variance (ANOVA) or Chi-square test, depending on type of variable. For the main outcome (HRQoL measured by the PLC at short-term follow-up), an analysis of covariance (ANCOVA) was calculated for the summed PLC scores at short-term follow-up, employing intervention arm as a grouping factor and baseline value as covariate. Our two hypotheses were addressed by Helmert

contrasts. Contrast 1 compared wait-list control vs. both active treatments; contrast 2 compared MBSR vs. the active control group. The same procedure was followed for secondary outcomes.

Substantial intercorrelation occurred among secondary variables at baseline. Therefore, to prevent type I errors, we also performed, as supplementary analysis, a single repeated-measures multivariate analysis of covariance using the change scores of seven secondary health-related inventory measures (factor *time*, two levels, level 1: changes from baseline to end of intervention, level 2: changes from baseline to short term follow-up) with a grouping factor (*group*, 3 levels) and the baseline values of the seven scales as covariates to control for baseline differences (the mindfulness index was excluded because it is not a demonstrated measure of health-related outcome but a variable to indicate manipulation control).

3 Results

Participants

Overall, 376 patients contacted us, of whom 330 individuals underwent required preliminary telephone screening (see Fig. 1 flowchart). Telephone-reported complaints of 52 individuals were not consistent with eligibility criteria, and an additional 147 declined participation, citing unavailability due to the time demands, travel requirements, scheduling problems, lack of interest or unspecified reasons. Clinic appointments were made with 187 women, and 177 were included into the trial (see Fig. 1).

The criteria for inclusion into the ITT sample were randomization and, for those not in the wait-list arm, participation in at least one session of a course. This procedure was chosen because intervention instructors were able to exclude patients before commencement of intervention on the basis of new information they had acquired during the intake interview




Figure 1: Patient flow chart according to the revised CONSORT statement [2]

(e.g. suicidal tendencies), which occurred after randomization. The ITT sample consisted of $N = 168$ women. The completer sample comprised all patients who had participated in at least 50% of the allocated intervention and provided data at both pre-intervention and short-term follow-up ($N=137$, drop-out rate, 18%). All patients were recruited between July 2004 and October 2005.

The average age of participants was 52.5 years ($SD=9.6$); average reported duration of symptoms 14.3 years ($SD=10.2$); and mean time since diagnosis of 4.0 years ($SD=3.9$). Demographic information is presented separately for each intervention arm of the study in Table 1. There were no significant baseline differences for sociodemographic or disease-related parameters. Regarding comorbidity, 58% of the patients had a clinically relevant depression score (i.e. score > 23 in the German version of the CES-D scale). Furthermore the sample showed an elevated degree of trait anxiety (*mean* STAI, 50.0, $SD=10.3$), higher than that of 89% of women aged 30-59 and 80% of women aged 60 or more in the German norm population. Regarding physical symptoms measured by the complaint list (GCP), our sample scored worse than 96% of the German norm population of same sex and age.

Table 1 Baseline characteristics for the three groups

Characteristic	Wait-list	Active Control	Mindfulness	p-value
N	59	56	53	
Mean age, \pm SD	52.3 \pm 10.9	51.9 \pm 9.2	53.4 \pm 8.7	.70
Family Status, %				.053
married	61.0	58.9	52.8	
married, living sep.	6.8	1.8	1.9	
widow	0	0	9.4	
divorced	11.9	17.9	18.9	
single	20.3	19.6	15.1	
missing	0	1.8	1.9	
Work, %				.94
working	37.3	41.1	35.8	
unemployed	10.2	12.5	7.5	
school	1.7	0	0	

housewife	6.8	8.9	11.3	
retired	35.6	28.6	37.7	
none of this	6.8	7.1	5.7	
missing	1.7	1.8	1.9	
Education Level, %				.25
no school completed	1.7	0	1.9	
9 years	30.5	28.6	34.0	
11 years/GCSE	25.4	39.3	41.5	
A-level/college entry level	42.4	30.4	20.8	
missing	0	1.8	1.9	
Duration of FM, <i>months</i> ± <i>SD</i>				
onset of disease	154.5 ± 117.2	188.0 ± 132.0	173.9 ± 119.1	.34
since diagnosis	44.4 ± 47.7	46.0 ± 43.7	54.6 ± 48.7	.48
Tenderpoint count	15.7 ± 2.3	15.1 ± 2.3	15.2 ± 2.5	.37

Analysis of primary outcome at short-term follow-up. Employing Helmert contrasts within an ANCOVA analyses adjusting for baseline levels of respective measures, there were no significant differences for any contrasts (contrast 1: wait-list control vs. both active treatments; contrast 2: MBSR vs. the active control group) between groups at short-term follow-up for the primary outcome HRQoL measured by the PLC. The p-values were $p = .70$ and $p = .20$ respectively (see Table 2).

Table 2 Comparison between groups by ANCOVA with short term evaluation results as dependent variable and baseline as covariate. Hypotheses are tested by Helmert Contrasts.

Variable	Helmert Contrast 1:	Helmert Contrast 2:	Main effect for Group	
	Waitlist vs. both active treatments	MBSR vs. Active Control	<i>(df = 2/164)</i>	
	p-Value	p-Value	F	p-Value
HRQoL (PLC)	.70	.20	0.902	.41
FIQ	.95	.36	0.431	.65

CES-D	.41	.19	1.208	.30
STAI	.04*	.19	2.871	.06
PSQI	.47	.74	0.316	.73
PPS _{affective}	.18	.18	1.805	.17
PPS _{sensory}	.89	.60	0.152	.86
FMI	.48	.03*	2.556	.08
GCQ	.32	.22	1.249	.29

HRQoL = Health Related Quality of Life, PLC = Quality of Life Profile for the Chronically Ill, FIQ = Fibromyalgia Impact Questionnaire, CES-D = Center for Epidemiological Studies depression inventory, STAI = State-Trait-Anxiety-Inventory, PSQI = Pittsburgh Sleep Quality Index, PPS = Pain Perception Scale, FMI = Freiburg Mindfulness Inventory, GCQ = Giessen Complaint Questionnaire,* $p < .05$.

Multivariate ANCOVA of secondary health-related outcome measures adjusting for baseline differences. This analysis was performed to account for type I errors due to the substantial intercorrelations of secondary variables at baseline. Analyses revealed no effects of *Time* (*Wilks Lambda*=.943, $F=1.32$, $df=7/152$ $p=.25$) or *Group* (*Wilks Lambda*=.883, $F=1.40$, $df=14/304$, $p=.15$) but showed a significant *Group X Time* interaction (*Wilks Lambda*=.851, $F=1.82$, $df=15/304$, $p<.05$). Two significant individual contrasts could also be identified (Table 2). The active treatment groups showed greater post-intervention reductions in anxiety than the wait-list patients ($p = .04$, contrast 1). Patients in the MBSR group rated themselves higher on the mindfulness scale (FMI) than patients allocated to active control group ($p = .03$, contrast 2). There were no significant differences for any other contrasts.

Table 3 reports means of primary and secondary outcome measures for baseline, end of intervention and short-term follow-up for each group and for the whole cohort. *P*-values represent within-group effects of these between baseline and short-term follow-up and the respective effect sizes are provided. The primary outcome HRQoL showed a significant positive change over time for the whole cohort ($p=.004$). For within-group analyses, this

comparison was also significant for the mindfulness group ($p=.02$; within-group pre-post effect size $d=0.39$), but not for the active control group or the wait-list condition. For the eight secondary outcome variables the following results were found: Overall, patients significantly improved in all variables from baseline to short-term follow-up, except self-attribution of mindfulness. In the wait-list group, two variables showed significant within-group pre-to-post-intervention changes (affective pain perception and complaints). For the active control group, three of eight variables showed a significant positive change over time. In the mindfulness group, five variables were significant at the $p\leq.01$ level and one at the $p\leq.05$ level. Effect sizes range from $d=0.19$ to $d=0.50$ for the mindfulness group, from $d=-0.09$ to $d=0.30$ for the active control group and from $d=-0.08$ to $d=0.25$ for the wait-list control group.

Insert Table 3 about here

Clinically significant changes

Bennett et al. [6] empirically determined a 14% change in the FIQ as a minimal clinically important difference (MCID). Overall 43 patients (26%) showed at least a 14% improvement and 22 (13 %) at least an impairment of the same size between baseline and short term follow-up. There were no group differences in improvement or impairment. Improvement rates were 22% for waitlist, 25% for active control and 30% for mindfulness respectively.

For the German CES-D scale, a score above 23 indicates a clinical relevant depression score. Thirty-nine patients (23 %) showed an improvement by crossing this cut-off point in a positive direction from baseline to short-term follow-up. On the other hand 17 patients (10%) crossed this threshold in the opposite direction. Improvement rates were unrelated to group allocation with 19% for waitlist, 23 % for active control and 28 % for MBSR respectively.

Table 3 Means and standard deviations reported for all variables per group for all three timepoints, baseline (BL), end of intervention (EoI) and short-term follow-up (STF).

Higher values on the PLC, indicate better health status. For all other scales, lower values indicate greater wellbeing..

	Wait-list (N = 59)					Active Control (N= 56)					Mindfulness (N = 53)					Overall (N=168)	
	BL	EoI	STF	p*	ES**	BL	EoI	STF	p	ES	BL	EoI	STF	p	ES	p	ES
HRQoL (PLC)	11.67 ± 3.18	11.80 ± 3.48	12.29 ± 3.28	.11	0.19	11.75 ± 3.27	12.89 ± 3.43	12.16 ± 3.61	.34	0.13	11.69 ± 2.94	12.64 ± 2.98	12.83 ± 3.06	.017	0.39	.004	0.23
FIQ	5.65 ± 1.86	5.32 ± 1.62	5.29 ± 1.66	.10	0.19	5.50 ± 1.68	5.08 ± 1.57	5.33 ± 1.90	.49	0.10	5.84 ± 1.37	4.90 ± 1.74	5.23 ± 2.00	.021	0.45	.007	0.22
CES-D	25.43 ± 9.26	24.22 ± 10.28	24.00 ± 9.61	.18	0.15	22.92 ± 10.27	20.90 ± 9.53	22.55 ± 10.13	.79	0.04	25.19 ± 9.60	23.20 ± 9.04	21.70 ± 9.93	.012	0.36	.018	0.18
STAI	48.68 ± 10.68	48.39 ± 9.92	49.18 ± 10.47	.63	-0.05	49.8 ± 10.91	48.00 ± 8.94	48.44 ± 10.94	.17	0.12	51.60 ± 9.18	47.65 ± 8.43	47.86 ± 9.12	.003	0.41	.022	0.14
PSQI	11.12 ± 4.36	10.68 ± 4.42	10.37 ± 4.06	.17	0.17	11.37 ± 4.24	10.12 ± 4.21	10.25 ± 4.09	.015	0.27	11.31 ± 3.45	10.04 ± 3.76	10.01 ± 3.60	.004	0.38	<.001	0.26
PPS affective	34.78 ± 7.66	33.09 ± 7.78	32.38 ± 9.07	.026	0.25	34.74 ± 8.67	31.96 ± 9.02	32.17 ± 8.76	.027	0.30	35.47 ± 9.38	31.26 ± 8.78	30.79 ± 9.20	<.001	0.50	<.001	0.35
PPS sensory	22.64 ± 5.65	21.17 ± 5.75	21.44 ± 5.34	.09	0.21	22.85 ± 6.58	22.56 ± 5.93	21.87 ± 5.40	.17	0.15	22.35 ± 6.12	20.78 ± 4.98	21.16 ± 5.42	.06	0.19	.004	0.18
FMI	36.67 ± 6.64	36.00 ± 5.28	36.13 ± 7.27	.48	-0.08	35.86 ± 7.81	36.99 ± 7.38	35.14 ± 7.61	.38	-0.09	36.38 ± 6.10	39.20 ± 5.03	37.66 ± 5.15	.11	0.21	.95	0.00
GCCQ	48.36 ± 14.79	47.41 ± 14.30	45.29 ± 15.04	.025	0.21	47.02 ± 14.65	43.41 ± 15.76	43.91 ± 15.10	.022	0.21	48.43 ± 13.53	42.01 ± 10.63	42.63 ± 12.20	<.001	0.43	<.001	0.28

*p-values represent within-group changes from baseline (BL) to short-term follow-up (STF) as well as for the whole cohort. **Within-group effect sizes reflect differences between t1 and t3 calculated by the mean difference divided by the standard deviation at baseline, positive effect sizes indicate improvement. For abbreviations see legend to Table 2.

On the PSQI a score of 5 or less is considered as being a good sleeper having no insomnia. Only 19 patients (11%) who scored higher at baseline reached this cut-off at short term follow-up. In contrast 9 patients (5%) who reported as being good sleepers at baseline crossed the threshold in the opposite direction. Positive change rates were 10% for wait list, 7 % for active control and 17 % for mindfulness respectively.

Medication

We compared the use of medication with simple dichotomous variables (yes/no) at baseline and at short-term follow-up for antidepressants, pain killers and sleep medication. There were no baseline differences for any of these variables. Only antidepressant medication was reduced significantly from baseline (45.7%) to short-term follow-up (35.0 %) ($p=.01$, $\chi^2=5.94$, $N=140$, McNemar Test), but there was no effect of group.

Course attendance

Patients showed similarly high attendance rates for both interventions. On average patients in the MBSR arm attended 6.7 of 8 sessions (84 %) and 6.2 of 8 (77%) in the active control (no significant difference between groups).

Role of self-attribution of mindfulness for health status changes

Associations were examined between change in self-attributed mindfulness (FMI) and changes in the other 8 questionnaire scores for the two active groups. In the MBSR arm, positive change in self-reported mindfulness was related to reduced anxiety, improved depressive symptoms, and improved HrQoL ($r's = .33 - .54$). For the active control group the same pattern emerged, with six of eight correlations reaching significance (depressive symptoms, HrQoL, FIQ, physical symptoms, affective pain perception anxiety, $r's = .27 - .63$).

Interview Data

At the end of the program patients rated the extent to which they had attained personal goals stated in the pre-intervention interview (goal attainment scaling; GAS [30]). Also a visual analog scale of overall impairment at pre- and post-intervention were compared. These data were collected exactly as in the forerunner study [21] in a short questionnaire during the interview and are reported in Table 4. Because we, unexpectedly, did not replicate major findings of the earlier study, we compared the goal attainment and visual analog findings between the two studies (Table 4) to facilitate interpretation of results. Examination of the 95% confidence intervals revealed no differences between studies in either of these measures.

Table 4 Results for the interview data for this study and the study by Grossman et al. [21].

		Active Control				Mindfulness			
		Mean	SD	ES	N	Mean	SD	ES	N
		(95% CI)				(95% CI)			
Impairment by Fibromyalgia	this study	10.39	32.11	0.49	36	18.83	24.16	0.86	42
		(-0.10 - 20.88)				(11.52 - 26.14)			
	Grossman et al. [21]	-7.62	29.52	-0.32	13	14.87	23.49	0.73	39
		(-23.67 - 8.43)				(7.51 - 22.24)			
GAS score	this study	0.58	2.13		38	1.27	1.34		42
		(-0.10 - 1.26)				(0.86 - 1.68)			
	Grossman et al. [21]	-1.26	1.91		13	1.31	2.27		34
		(-2.3 - -0.22)				(.55 - 2.07)			

95% CI = 95% Confidence Interval. Impairment by FM is the difference between end of intervention and baseline for data from visual analog scales (0-100 mm), positive results indicate an improvement. Goal attainment scores (GAS) reflect whether goals specified at baseline have been reached at end of intervention. A mean of 0 reflects that the goal has just been reached while values larger than 0 indicate that the result was much better than expected before the intervention. Data from this study is based on the per protocol sample with one data set missing for the mindfulness group.

4 Discussion

We conducted a randomized, partially blinded, three-armed trial, with adequate statistical power, to investigate the effects of a mindfulness-based intervention upon HRQoL and other parameters of wellbeing among female fibromyalgia patients. Comparisons were made between MBSR, an active control intervention, and a wait-list group. In each set of analyses, no group effects upon HRQoL were found. Therefore the MBSR intervention did not yield the hypothesized effects and did not prove to be better than either a simple wait-list procedure or an active control condition designed to match for non-specific aspects. On the basis of the results of this trial MBSR cannot be recommended as an effective treatment for women suffering from fibromyalgia.

An examination of the eight secondary variables, employing two comparisons revealed only two significant effects out of 16 contrasts considered. Namely, the active treatment groups showed greater post-intervention reductions in anxiety than the wait-list patients. Additionally, MBSR patients rated themselves higher on the mindfulness scale than active control patients.

Despite the overall negative findings, examination of within-group pre- to post-effect sizes (Table 3) may, nevertheless, reveal relevant additional information. On average, patients of all groups showed slight improvements over the course of the trial. Average within-group effect sizes from baseline to short term follow-up ranged from $d=-0.08$ to 0.25 ($mean=0.14$) for waitlist, from $d=-0.09$ to 0.30 ($mean=0.14$) for active control and from $d=0.19$ to 0.50 ($mean=0.37$) for MBSR. Differences in effect sizes between MBSR ($mean=0.37$) and the two other treatments ($mean=0.14$) were too small to show either statistical or clinical significance. Nevertheless, a multivariate analysis of secondary outcomes adjusting for baseline differences indicated a significant *group x time* interaction which reflected the somewhat larger pre-to-post effects of the MBSR group. These post-hoc findings are merely informative and in no

way should be construed to be at variance with the failure to find differential benefits of MBSR for the primary outcome.

Confronted by the inconsistencies between the current findings and those of the forerunner study, we examined the data for clues that might shed light on why this may have occurred. For example, in the present investigation, the additional quantitative data derived from personal interviews of the two active treatments before and after the intervention do not fit the overall picture of the standardized inventories: In the post-intervention interviews, patients in the MBSR arm reported substantial improvements, and large effect sizes were found, on a self-rated global scale that estimated perceived lessening of fibromyalgia-related impairment. Patients also indicated that they had achieved personal goals exceeding the level expected at baseline (Table 4). Similar, although smaller, effects were found for the active control group. In general, these quantitative interview data also matched what was found among MBSR participants in the earlier study [21].

It is also striking that results of the main questionnaire data of this trial, especially the primary outcome measure, are in sharp contrast to the outcome of the earlier study [21], which was very similar in design, intervention, outcome variables and actual MBSR instructors. Although patients in the two studies were comparable at baseline levels, only the Grossman et al. [21] study showed a marked improvement after MBSR intervention. The within-group post-intervention effect size for the HrQoL sum score was $d=0.93$ vs. $d=0.39$ in the current study.

One possible reason for the latter discrepancy could be the fact that the self-report questionnaire data in the current investigation might have been biased due to excessive patient burden: In the present study, questionnaires were usually filled out during the visit to the hospital, after patients had been instrumented with the LifeShirt for later 24-h monitoring and had undergone a calibration procedure (controlled breathing and walking). Indeed, over the course of the study, more and more patients complained of discomfort during this assessment.

Additionally, some patients felt too exhausted to complete questionnaires during the visit and were allowed to complete inventories at home and return them the next day. This led to inconsistency in the setting, and, in retrospect, may have caused significantly greater error variance in results of the current investigation.

Other aspects of the current investigation may have also added to overall patient burden, especially when common symptoms of fibromyalgia are considered (e.g. fatigue, lack of energy and reduced threshold to discomfort). During the LifeShirt assessment, patients were prompted approximately every 45 minutes to fill in an electronic diary. They were also requested to change equipment batteries, and to connect a pulse oximetry sensor for assessment during sleep. Furthermore, patients were asked to keep diaries of their homework and medications during selected weeks, as well as to complete a questionnaire every four weeks about changes in medication and concurrent therapies. On the other hand, in the first study, patient burden was much lower, since no ambulatory or physiological monitoring was performed, and questionnaire completion was less demanding and always performed in the same location.

Other crucial differences between the studies had to do with issues of recruitment and assignment to treatments: In the present study, two-thirds of the sample was randomly assigned to one of two plausible active, behavioral interventions. Thus, patients were provided information that presented two rather vaguely described interventions. Potential benefits were mentioned but not further specified. This approach may have influenced motivation of our patients quite differently from those in the earlier quasi-randomized study.

In the earlier study, patients actively chose mindfulness training upon enrollment, based upon either referrals from physicians who were often enthusiastic about the specific benefits of mindfulness training, or after having read a brochure positively describing the program and its potential benefits. Therefore, the treatment preferences of patients in the former study were always concordant with the intervention received.

Potent influences of patient preferences upon effects of treatment have repeatedly been demonstrated [13,28,39]. Patient preference and resulting effects upon motivation are important and typically neglected issues in randomized controlled trials of behavioral interventions, especially because such trials commonly require substantial commitment and effort. It seems plausible that these factors may have contributed to the differences between the previous and current trials. Therefore, while the present investigation can be considered a better controlled study, due to its stringent randomization procedure and more elaborate methodology, these very features may also have brought with them distinct vulnerabilities that commonly go ignored regarding the ecological and external validity of results.

Indeed, the current trial's failure to find beneficial effects of MBSR in the primary outcome, as well the relatively meager evidence of improvements in secondary measures, are not easy to reconcile with results of the earlier investigation, unless one considers these methodological differences relating to patient burden, recruitment and randomization procedure. Therefore, when designing trials in the future, it may be important to keep in mind the characteristics of participation in behavioral interventions in real life: Usually, patients deliberately choose to attend an MBSR course, and are not merely assigned to a mindfulness program. Furthermore, they are typically not part of an extensive monitoring procedure. In these respects, the earlier investigation conformed more to what occurs under naturalistic conditions.

Two other issues regarding specific limitations of the present investigation should also be mentioned: As previously reported, patients were told before randomization that both active treatments were of equal value. However, patients may not have perceived treatment as equivalent. As a post-hoc check of the credibility of this claim, we assessed the post-trial treatment choices of participants who had been randomized to the wait-list group and were later free to choose between interventions. Of 59 patients, 35 chose MBSR, 10 chose the

active control group and 14 did not participate in any treatment. The fact that MBSR was more frequently chosen may indicate that patients deemed it the more promising treatment.

Another point to consider is that fidelity of interventions was not monitored during the study. Both interventions often dealt with personal emotional issues and required an atmosphere of trust. We chose against monitoring due to concerns that it might be disruptive or influence the intervention in some other undesired manner. Nevertheless, instructors in both arms were carefully supervised and highly experienced in their group intervention techniques. For example, instructors in the experimental intervention (MBSR) had taught for many years, continuously conferred with each other and followed the same weekly syllabus. Nevertheless, we cannot be absolutely sure of strict treatment fidelity.

In conclusion, despite the current, clearly negative findings, this report may provide additional and valuable information regarding commonly neglected factors likely to influence assessment of behavioral interventions, in general, and MBSR efficacy in fibromyalgia, in particular. We believe our findings demonstrate the value that can be derived from replicating research with essentially identical interventions and similar patient groups, while, at the same time, varying methodological aspects. Thus our results do point to the necessity of further, and even more carefully conceived and executed trials that take into account the necessity for both methodological stringency and ecological validity.

Acknowledgement

This study was supported by the Samuelli Institute, Alexandria, VA, USA and by the Manfred Köhnlechner Stiftung, Munich, Germany.

Conflict of Interest Statement:

No financial or other conflicts of interest exist for any of the authors.

Reference List

- [1] Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative Review: The Pathophysiology of Fibromyalgia. *Annals of Internal Medicine* 2007;146:726-734.
- [2] Altman DG, Schulz KF, Moher D, Egger MJ, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Annals of Internal Medicine* 2001;134:663-694.
- [3] Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. *Pain* 2005;119:5-15.
- [4] Astin JA, Berman BM, Bausell B, Lee W-L, Hochberg M, Forsys KL. The efficacy of mindfulness meditation plus qigong movement therapy in the treatment of fibromyalgia: A randomized controlled trial. *Journal of Rheumatology* 2003;30:2257-2262.
- [5] Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. *Journal of Psychosomatic Research* 2002;53:737-740.
- [6] Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. *The Journal of rheumatology* 2009;36:1304-1311.
- [7] Bigelow SL. *Fibromyalgia. Simple Relief through Movement*. New York: Wiley, 2000.
- [8] Brähler E, Scheer J. *Der Gießener Beschwerdebogen (GEB)*. Bern: Hans Huber, 1983.
- [9] Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. *Journal of Rheumatology* 1991;18:728-733.

- [10] Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Research* 1989;28:193-213.
- [11] Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. *Journal of Psychosomatic Research* 1998;45:5-13.
- [12] Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. *The Spine Journal* 2007;7:541-546.
- [13] Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, Seagal RJ. Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy. *Cancer* 2008;112:1845-1853.
- [14] Creamer P, Singh BB, Hochberg M, Berman BM. Sustained improvement produced by nonpharmacologic intervention in fibromyalgia: Results of a pilot study. *Arthritis Care and Research* 2000;13:198-204.
- [15] Crofford LJ. Meta-Analysis of antidepressants in fibromyalgia. *Current Rheumatology Reports* 2001;3:115.
- [16] Crofford LJ, Mease PJ, Simpson SL, Young J, Martin SA, Haig GM, Sharma U. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. *Pain* 2008;136:419-431.
- [17] Geissner E. Die Schmerzempfindungsskala (SES). Handanweisung. Göttingen: Hogrefe 1996.
- [18] Goldenberg DL, Burckhardt CS, Crofford LA. Management of fibromyalgia syndrome. *JAMA* 2004;292:2388-2395.

- [19] Goldenberg DL, Kaplan KH, Nadeau MG, Brodeur C, Smith S, Schmid CH. A Controlled Study of a Stress-Reduction, Cognitive Behavioral Treatment Program in Fibromyalgia. *Journal of Musculoskeletal Pain* 1994;2:53-66.
- [20] Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health benefits: A meta-analysis. *Journal of Psychosomatic Research* 2004;57:35-43.
- [21] Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: Evidence of postintervention and 3-year follow-up in wellbeing. *Psychother Psychosom* 2007;76:226-233.
- [22] Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, and the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. *Mayo Clinic Proceedings* 2002;77:371-383.
- [23] Häuser W, Bernardy K, Arnold B, Offenbacher M, Schiltenswolf M. Efficacy of Multicomponent Treatment in Fibromyalgia Syndrome: A Meta-Analysis of Randomized Controlled Clinical Trials. *Arthritis & Rheumatism-Arthritis Care & Research* 2009;61:216-224.
- [24] Hautzinger M, Bailer M. Allgemeine Depressionsskala (ADS)- Manual. Weinheim: Beltz, 1992.
- [25] Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. *Clinical and Experimental Rheumatology* 2001;19:697-702.
- [26] Kabat-Zinn J. Full catastrophe living : using the wisdom of your body and mind to face stress, pain, and illness. New York, N.Y.: Bantam Dell, 1990.
- [27] Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. *Journal of Behavioral Medicine* 1985;8:163-190.

- [28] Kalauokalani DM, Cherkin DCP, Sherman KJP, Koepsell TDM, Deyo RAM. Lessons from a Trial of Acupuncture and Massage for Low Back Pain: Patient Expectations and Treatment Effects. [Miscellaneous Article]. *Spine* 2001;26:1418-1424.
- [29] Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The Impact of a Meditation-Based Stress Reduction Program on Fibromyalgia. *General Hospital Psychiatry* 1993;15:284-289.
- [30] Kiresuk TJ, Sherman RE. Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. *Community Mental Health Journal* 1968;4:443-453.
- [31] Laux L, Glanzmann P, Schaffner P, Spielberger CD. *Das State-Trait-Angstinventar (STAI-G)*. Weinheim: Beltz, 1981.
- [32] Lush E, Salmon P, Floyd A, Studts J, Weissbecker I, Sephton S. Mindfulness Meditation for Symptom Reduction in Fibromyalgia: Psychophysiological Correlates. *Journal of Clinical Psychology in Medical Settings* 2009;16:200-207.
- [33] Mannerkorpi K, Arndorw M. Efficacy and feasibility of a combination of body awareness therapy and qigong in patients with fibromyalgia: a pilot study. *Journal of Rehabilitation Medicine* 2004;36:279-281.
- [34] Marquis P, Chassany O, Abetz L. A comprehensive Strategy for the Interpretation of Quality-of-Life Data Based on Existing Methods. *Value in Health* 2004;7:93-104.
- [35] Marsaglia G, Zaman A. A new class of random number generators. *The Annals of Applied Probability* 1991;1:462-480.
- [36] Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. *Arthritis and Rheumatism* 1998;41:1966-1971.

- [37] Morone N, Greco C, Weiner D. Mindfulness Meditation for the treatment of chronic low back pain in older adults: A randomized controlled pilot study. *Pain* 2008;134:310-319.
- [38] Offenbaecher M, Waltz M, Schoeps P. Validation of a German version fo the fibromyalgia impact questionnaire (FIQ-G). *Journal of Rheumatology* 2000;27:1984-1988.
- [39] Preference Collaborative Review Group. Patients' preferences within randomised trials: systematic review and patient level meta-analysis. *BMJ* 2008;337:a1864.
- [40] Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Applied Psychological Measurement* 1977;1:385-401.
- [41] Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. *Pain* 2008;136:432-444.
- [42] Sephton SE, Salmon P, Weissbecker I, Ulmer C, Floyd A, Hoover K, Studts JL. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: results of a randomized clinical trial. *Arthritis & Rheumatism* 2007;57:77-85.
- [43] Siegrist J, Broer M, Junge A. Profil der Lebensqualität chronischer Kranker. Manual. Göttingen: Beltz Test, 1996.
- [44] Solas. for missing data analysis 2.0. Cork, Ireland: Statistical Solutions Ltd, 1999.
- [45] Spielberger CD. Manual for the State-Trait Anxiety Inventory: STAI (Form Y). Palo Alto, CA: Consulting Psychologists Press, 1983.
- [46] Walach H, Buchheld N, Buttenmüller V, Kleinknecht N, Schmidt S. Measuring mindfulness - the Freiburg Mindfulness Inventory (FMI). *Personality and Individual Differences* 2006;40:1543-1555.

- [47] Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. *Arthritis & Rheumatism* 1995;38:19-28.
- [48] Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin MC, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. *Arthritis & Rheumatism* 1990;33:160-172.

¹ Manuals for both intervention arms are available in German from the first author.

² According to our study protocol, the primary endpoint of this trial was the German version of the Fibromyalgia Impact Questionnaire (FIQ-G). However after examining questionnaire data---but before any analysis had been done and before unblinded as to group allocation--we found that due to some misleading instruction in the German translation, several patients had not correctly completed six visual analogue scales which are the backbone of this instrument. Overall, we missed data of 18 patients because of this problem. After considering various imputation procedures for the missing data, we decided that replacement of such a substantial portion of missing data would represent an unsatisfactory approach. We thus decided to replace the primary outcome with one of the secondary outcomes, i.e. The Quality of Life Profile for the Chronically Ill (PLC) a measure of HRQoL. Our external Scientific Advisory Committee of experts otherwise unrelated to this trial, agreed to this decision. The committee consisted of Frank Wilhelm, University of Basel, Wolfgang Langewitz, University Hospital Basel, and Klaus Linde, Technical University Munich. A corresponding amendment was submitted to the ethics committee. We also marked this change in the record of the trial (identifier NCT00106275) on clinicaltrials.gov. This decision was made without any knowledge of the analyzed data or outcome.